<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762540</url>
  </required_header>
  <id_info>
    <org_study_id>GK_nilani_2012</org_study_id>
    <nct_id>NCT01762540</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Induced Whole Body Catabolisme</brief_title>
  <official_title>Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the trial is to advance our knowledge on the possible mechanism
      underlying the catabolic effects of long-term treatment with glucocorticoid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term treatment with glucocorticoid induces a general state of catabolism and increases
      insulin resistance. The underlying mechanisms are insufficiently characterized, however
      glucocorticoid induced changes of Growth Hormone (GH) and the Insulin-like growth factor I
      (IGF-I) appear to be of outmost importance.

      We wish to investigate the mechanism behind glucocorticoid induced catabolism and insulin
      resistance.

      More specific we wish to investigate:

        -  Whether glucocorticoid induces IGF-I inhibiting substances in serum or interstitial
           fluid that block the ability of IGF-I to phosphorylate its receptor in vitro

        -  Whether glucocorticoid inhibits intracellular IGF-I and insulin signaling in vitro and
           in vivo

        -  The mechanisms by which growth hormone counteracts the CG-mediated inhibition of IGF-I
           action
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin-like Growth Factor (IGF)-I profiles of subjects before and after prednisolone-treatment.</measure>
    <time_frame>day 1, 3 and 5</time_frame>
    <description>Blood-test before (day 1) during (day 3) and at the end (day 5) of placebo/prednisolone treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracellular signaling of IGF-I under the influence/abscence of prednisolone.</measure>
    <time_frame>day 5</time_frame>
    <description>Tissue biopsy on day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity under the influence/abscence of prednisolone.</measure>
    <time_frame>Day 5</time_frame>
    <description>Hyperinsulinemic euglycemic clamp on day 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Whole Body Catabolisme Induced by Glucocorticoids</condition>
  <arm_group>
    <arm_group_label>Calcium supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule with tablet of calclium supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsule with tablet of Prednisolone 37,5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Prednisolone 37.5 mg x1 for 5 days</description>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Supplement</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Calcium supplement</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  healthy subjects

          -  sex: male

          -  age 20-30 years

          -  BMI 19-26 kg/m2

          -  normal HbA1c

        Exclusion Criteria:

          -  suspected og known allergy to the trial drug or similar medications.

          -  known current illness including diabetes mellitus, ischemic heart disease or cardiac
             arrhythmia.

          -  Daily drug intake (excluding Over-the-Counter medicines).

          -  Known or previous mental illness

          -  Current participation or previous participation in experiments using ionizing
             radiation for a year prior to inclusion in this study.

          -  Participation in a larger X-ray examinations in trial period.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frystyk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Laboratory, Clinical Institute of Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Protein breakdown</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Glucose intolerance</keyword>
  <keyword>Lipolysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

